Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CL2A-SN-38 is a drug-linker conjugate consisting of SN-38, a potent DNA topoisomerase I inhibitor, and linker CL2A, for the manufacture of antibody drug conjugates (ADCs). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a nonclaevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | 5 days | $ 148.00 | |
5 mg | 5 days | $ 315.00 | |
10 mg | 5 days | $ 481.00 |
Description | CL2A-SN-38 is a drug-linker conjugate consisting of SN-38, a potent DNA topoisomerase I inhibitor, and linker CL2A, for the manufacture of antibody drug conjugates (ADCs). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a nonclaevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond[1]. |
Molecular Weight | 1480.61 |
Formula | C73H97N11O22 |
CAS No. | 1279680-68-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 85 mg/mL (57.4 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CL2A-SN-38 1279680-68-0 Others CL2A CL2A SN 38 bystander effect SN-38 antitumor Inhibitor Drug-Linker Conjugates for ADC inhibit DNA Topoisomerase I ADC CL-2A-SN-38 CL2ASN38 inhibitor